Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.

Appl Radiat Isot

Green Templeton College and Particle Therapy Cancer Research Institute, University of Oxford, Oxford, UK.

Published: December 2011

The purpose of this analysis was to assess the potential of BNCT, with L-boronophenylalanine (L-BPA), as first line radiotherapy for glioblastoma multiforme (GBM). The survival of patients with newly diagnosed GBM from a phase II BNCT study was compared with those from the two arms of a phase III study with conventional radiotherapy (RT) vs. RT plus concomitant and adjuvant medication with temozolomide (TMZ). A small subgroup, for which the methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) DNA-repair gene was known, was also considered. The results indicated that the use of BNCT with BPA should be explored in a stratified randomized phase II trial in which patients with the unmethylated MGMT DNA-repair gene are offered BNCT vs. RT plus TMZ.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apradiso.2011.03.022DOI Listing

Publication Analysis

Top Keywords

newly diagnosed
8
glioblastoma multiforme
8
mgmt dna-repair
8
dna-repair gene
8
boron neutron
4
neutron capture
4
capture therapy
4
therapy newly
4
diagnosed glioblastoma
4
multiforme assessment
4

Similar Publications

Background: Parasitic infections are known to suppress the cell mediated immunity that protects against tuberculosis. The status of parasitic infections among bacteriologically confirmed tuberculosis patients and their household contacts in Cameroon is not well established. This study aimed at reporting the status of parasitic infections in TB patients and their household contacts with keen interest in associated risk factors to disease exposure.

View Article and Find Full Text PDF

Aim: The study aimed to determine the incidence of adverse drug reactions (ADRs) among newly diagnosed tuberculosis (TB) patients receiving daily drug regimen with fixed-dose combination treatment under the National Tuberculosis Elimination Program.

Materials And Methods: A community-based prospective cohort study was carried out in the Udupi district. Over 12 months, all newly diagnosed TB patients of either gender were included from 63 primary health centers and 6 community health centers, and ADRs were recorded by personal interviews.

View Article and Find Full Text PDF

Background Different pathologies are encountered more often in human immunodeficiency virus (HIV)-infected patients, such as bacterial, fungal, viral infection, and neoplastic diseases. Recently, studies have shown that HIV-infected individuals have poorer oral health outcomes, worse dentition, and aggressive forms of periodontitis. This study aims to investigate the dental and periodontal status of HIV-infected patients, the correlation between CD4+ level and the CD4 percentage with dentition, and periodontal status.

View Article and Find Full Text PDF

Background: Acute myeloid leukemia (AML) with RAM immunophenotype is a newly recognized high-risk AML immunophenotypic subcategory characterized by blasts with bright expression of CD56 and weak to absent expression of CD45, HLA-DR, and CD38, as first described by the Children's Oncology Group (COG). The relationship between AML-RAM and other CD56-positive acute leukemias is unclear. The goal of this study is to characterize the clinicopathological characteristics of AML with RAM phenotype and compare them with other CD56 co-expressing acute leukemias.

View Article and Find Full Text PDF

Background: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.

Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.

Results: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!